EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics

Chen-Hsu Yu iD, Summer Y Y Ha iD, Zhiqiang An iD, Kyoji Tsuchikama iD, Wenbo Li iD

Antibody Therapeutics · 29.06.2026 · 9 (3) · 273-292

DOI: 10.1093/abt/tbag022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 29.04.2026. Verfasst von Chen-Hsu Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, U…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CPRIT cancer therapeutics and training program, Welch Foundation, Cancer Prevention and Research Institute of Texas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA-targeting therapeutics have enormous potential to precisely target disease-causing RNAs, extending beyond the traditional limits of “druggability” for small molecules, antibodies, and protein-targeting cell therapies. However, one crucial limitation is that RNA-targeting drug modalities (such as oligonucleotides) cannot effectively reach diseased tissue or cell types. Antibody-oligonucleotide conjugates (AOCs) emerge as a promising frontier in aiding RNA therapeutics by harnessing antibodies to deliver drug modalities to target specific RNAs in desired tissues or cells. In this Review, we summarize the critical components of AOCs, key considerations for their design and manufacturing, ongoing AOCs in preclinical/clinical development, and disease indications. We discuss the current hurdles to improving AOC efficacy and extending its application, concluding with an outlook on the unique opportunities offered by AOCs beyond traditional oligonucleotides and small-molecule antibody-drug conjugates. We propose that, with focused efforts to overcome key challenges, AOCs have the potential to transform RNA therapeutics, offering treatment options for many previously untreatable diseases.

Schlagwörter

Stichwörter der Autor:innen

RNA therapyantibody-oligonucleotide conjugate (AOC)genetic diseasesmulti-specific drugs

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, United States.
  • Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, United States.

ORCID-Profile: Chen-Hsu Yu, Summer Y Y Ha, Zhiqiang An, Kyoji Tsuchikama, Wenbo Li

Förderung

  • CPRIT cancer therapeutics and training program
  • Welch Foundation
  • Cancer Prevention and Research Institute of Texas
  • NIH

Zitieren

APA

Yu, C. H., Ha, S. Y. Y., An, Z., Tsuchikama, K., & Li, W. (2026). Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics. Antibody Therapeutics, 9(3), 273-292. https://doi.org/10.1093/abt/tbag022

Vancouver

Yu CH, Ha SYY, An Z, Tsuchikama K, Li W. Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics. Antibody Therapeutics. 2026;9(3):273-292. doi:10.1093/abt/tbag022

BibTeX
@article{Yu2026,
  author = {Yu, Chen-Hsu and Ha, Summer Y Y and An, Zhiqiang and Tsuchikama, Kyoji and Li, Wenbo},
  title = {Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics},
  journal = {Antibody Therapeutics},
  year = {2026},
  volume = {9},
  number = {3},
  pages = {273--292},
  doi = {10.1093/abt/tbag022}
}
Kostenlos starten →